智通财经APP讯，同仁堂国药(03613)发布公告，公司于近日收到柬埔寨王国(柬埔寨)卫生部药品与食品 司颁发的《传统药品注册许可证》("许可证")，准许将公司的"同仁堂安宫牛黄丸"在柬埔寨出售。 "同仁堂安宫牛黄丸"应遵照持证的中医师的指导下使用。另外，早前柬埔寨卫生部亦已颁发"同仁堂安 宫牛黄丸"进口许可证。 本次公司取得柬埔寨卫生部药品与食品司签发的许可证后，公司的"同仁堂安宫牛黄丸"可在柬埔寨出 售，有助于丰富公司重点产品的分销渠道，有利于公司的市场拓展。上述许可证的取得暂不会对公司生 产经营和业绩产生重大影响。药品销售容易受到柬埔寨政策环境变化、汇率波动、市场竞争等因素的影 响。 ...

格隆汇9月26日丨同仁堂国药(03613.HK)发布公告，公司于近日收到柬埔寨卫生部药品与食品司颁发的 《传统药品注册许可证》，准许将公司的"同仁堂安宫牛黄丸"在柬埔寨出售。本次本公司取得柬埔寨卫 生部药品与食品司签发的许可证后，公司的"同仁堂安宫牛黄丸"可在柬埔寨出售，有助于丰富公司重点 产品的分销渠道，有利于公司的市场拓展。 ...

桂林三金（002275.SZ）9月26日在投资者互动平台表示，公司产品在海外很多市场都有销售，如东欧的 塞尔维亚、美洲的美国和加拿大、大洋洲的澳大利亚、东南亚地区大部分国家等。但是目前没有在日韩 地区销售，也没有相关外企咨询合作代理。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问桂林三金西瓜霜含片是否在日韩有销售，是否有 相关国外企业咨询合作代理？ ...

Core Viewpoint - Dong'e Ejiao, a representative of Chinese time-honored brands, faces significant challenges in its recovery journey, including management turnover, strategic adjustments, and trust crises, despite reporting revenue and profit growth in the first half of 2025 [1] Group 1: Financial Performance - In the first half of 2025, Dong'e Ejiao achieved revenue of 3.051 billion yuan, a year-on-year increase of 11.02%, and a net profit attributable to shareholders of 818 million yuan, up 10.74% year-on-year [2] - However, the second quarter revenue dropped to 1.332 billion yuan, a decline of approximately 387 million yuan from the first quarter, with growth rate plummeting from 18.24% to 2.91%, indicating weakened growth momentum [2] - The company plans to distribute a cash dividend of 12.69 yuan per 10 shares, totaling 817 million yuan, which nearly exhausts the net profit for the first half of the year, raising concerns about its reinvestment capacity [2] Group 2: Product Structure and Growth Potential - Dong'e Ejiao heavily relies on its Ejiao product line, which generated 2.845 billion yuan in revenue, accounting for 93.24% of total revenue, while other products contributed only 142 million yuan, less than 5% [3] - Despite attempts to diversify with new products like "Peach Blossom Princess" and "Royal Weichang 1619," the company has not successfully established a significant second growth curve [3] - The over-reliance on a single product category weakens the company's risk resilience and limits its competitive edge in a challenging market [3] Group 3: Compliance and Brand Trust Issues - Since 2024, Dong'e Ejiao has faced multiple penalties for marketing violations, including misleading claims about product suitability for children, which lack scientific backing [4] - The company also encountered issues with price-related violations, further damaging its brand trust [4] - A significant incident in November 2024 involved the National Medical Insurance Administration reporting issues with the traceability codes of its products, which, although not directly attributed to the company, highlighted weaknesses in its supply chain and channel management [5] Group 4: Public Trust and Market Confidence - Dong'e Ejiao's high product pricing has made it a frequent target in "insurance fraud" incidents, raising concerns about its pricing transparency and integrity [5] - The company must address its marketing system and compliance management to restore public confidence in its brand, especially as consumers increasingly prioritize brand reputation and product authenticity [5] - The path to recovery for Dong'e Ejiao remains challenging, requiring strategic determination and reform efforts to cultivate new growth points and strengthen internal controls [6][7]

Market Overview - On September 26, the Traditional Chinese Medicine (TCM) sector declined by 0.38%, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the TCM sector included: - *ST Changyao: Closed at 3.88, up 3.47% with a trading volume of 134,100 shares [1] - Fangsheng Pharmaceutical: Closed at 12.08, up 2.11% with a trading volume of 274,600 shares [1] - Huaren Sanjiu: Closed at 28.39, up 1.50% with a trading volume of 133,600 shares [1] - Major decliners included: - Weikang Pharmaceutical: Closed at 23.66, down 6.30% with a trading volume of 81,000 shares [2] - Zhendong Pharmaceutical: Closed at 6.57, down 4.09% with a trading volume of 518,000 shares [2] - Zhongsheng Pharmaceutical: Closed at 17.00, down 2.41% with a trading volume of 295,000 shares [2] Capital Flow - The TCM sector experienced a net outflow of 298 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2] - Key stocks with significant capital flow included: - Huaren Sanjiu: Net inflow of 44.98 million yuan from institutional investors [3] - Fangsheng Pharmaceutical: Net inflow of 33.39 million yuan from institutional investors [3] - Dong'e Ejiao: Net inflow of 32.19 million yuan from institutional investors [3]

Core Viewpoint - The company has successfully completed the re-registration of its health food product, "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules," and received the registration certificate from the National Market Supervision Administration, indicating its compliance with regulatory standards [1] Group 1 - The product has undergone animal testing and has been evaluated to have health benefits that may help enhance immunity [1] - The registration number for the product is Guo Shi Jian Zhu G20200107, and it is valid until August 25, 2030 [1]

Group 1 - The company has been asked about the proportion of innovative drugs in its R&D plans for the year [2] - The company stated that its traditional Chinese medicine new drug, Cangrong Granules, is currently in the process of pilot-scale research [2] - Further details regarding the company's R&D plans will be available in the 2024 annual report [2]

Core Insights - The 2025 Hong Kong International Traditional Chinese Medicine Conference has commenced, focusing on promoting the high-quality global development of traditional Chinese medicine (TCM) [1] - The event gathered nearly 500 experts, scholars, and industry leaders from various regions, showcasing the practical value and development prospects of TCM through diverse activities [1][4] - The conference aims to explore new paths and opportunities for the internationalization of TCM, emphasizing collaboration among government, industry, academia, and research sectors [1] Group 1: Event Overview - The conference features a variety of activities, including rare herbal exhibitions, cultural experiences, product showcases, and lectures by renowned doctors, providing a platform for extensive communication [1][4] - The opening ceremony included a performance of "Ba Duan Jin" and Tai Chi, demonstrating the practicality of TCM in daily health management [4][6] Group 2: Key Speakers and Their Messages - Xu Zhengzhong, Chairman of the Zijing Cultural Group, highlighted TCM as a treasure of the Chinese nation, emphasizing its integration into Hong Kong's healthcare system and its role in the Greater Bay Area [8] - Liang Zhenying, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference, noted that Hong Kong's TCM sector has developed a complete and advanced system, integrating into the overall healthcare and wellness system [10] - Jia Zhongwu, Director of the Comprehensive Department of the National Administration of Traditional Chinese Medicine, stated that the Chinese government places high importance on the development of TCM, promoting its unique advantages in health initiatives [12] Group 3: Government Support and Future Directions - Chen Guoki, Secretary for Administration of the Hong Kong SAR Government, expressed the government's commitment to promoting high-quality TCM development, leveraging Hong Kong's unique advantages [15] - Wang Cuijun, General Manager of China Resources Group, emphasized the global collaboration needed for TCM's innovation and its role in building a healthy community [17] - The conference also launched the "High-Quality Development of the Traditional Chinese Medicine Industry Chain" initiative, aiming to foster collaborative development and cultural dissemination of TCM [21] Group 4: Conference Activities and Impact - The conference will last four days, featuring exhibitions, international summits, and community health services, showcasing TCM's cultural charm and development achievements [23] - The event aims to contribute to human health and well-being by promoting the innovative and open development of TCM [23]

Core Points - The "2025 Hong Kong International Traditional Chinese Medicine Conference" commenced in Hong Kong, focusing on promoting the high-quality global development of traditional Chinese medicine (TCM) [2][23] - The event gathered nearly 500 experts, scholars, and industry leaders from various regions, including over 130 exhibiting organizations, showcasing the practical value and development prospects of TCM [2][23] - The conference featured diverse activities such as rare herbal exhibitions, cultural experiences, product showcases, and lectures by renowned doctors, facilitating discussions on the internationalization of TCM [2][23] Group 1: Event Overview - The conference opened with a half-hour performance of "Ba Duan Jin" and Tai Chi, integrating traditional practices into modern urban life, which received enthusiastic responses from attendees [2][3] - Key figures in attendance included national and local government officials, industry leaders, and TCM experts, highlighting the significance of the event [4][6][9] Group 2: Government and Industry Support - The chairman of the organizing group emphasized TCM as a treasure of the Chinese nation, supported by the Hong Kong government through initiatives like establishing TCM hospitals and research centers [6][14] - The Hong Kong government is committed to promoting high-quality TCM development, leveraging its unique advantages in cultural resources and international medical systems [14][16] Group 3: Collaborative Initiatives - A "High-Quality Development of the Chinese Medicine Industry Chain and Cultural Co-Link Initiative" was launched, with representatives from major companies signing to promote collaborative development and cultural dissemination of TCM [21] - The conference aims to serve as a platform for global cooperation in TCM, enhancing product development, talent exchange, and market expansion [19][21] Group 4: Future Activities - The conference will last four days, featuring exhibitions, international summits, and community health services, showcasing TCM's cultural charm and development achievements [23]

【导读】 2025香港国际中医药大会在港启幕，以全球智慧共谋中医药高质量走向世 中国基金报记者 郭玟君 9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议 展览中心盛大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及 港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代 表，包括20余位院士、国医大师、岐黄学者，以及超过130家参展机构。大会通过稀有中药 材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展现中医药的实用价值 与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机 遇。 大会开幕式现场 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八 段锦、太极融入现代都市生活场景，为繁忙的"上班族"提供了简易的健身方式，现场观众反 应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多 名企展区，展出多种珍贵中药材，配以图文解说，帮助参观者深入了解药材特性与临床应 用，为大家提供了广阔的交流平台。 全国政协副主席梁振英， ...